EAE is a dynamic, multi-phase disease: the acute inflammatory peak typically occurs at days 12-18 post-immunisation in MOG35-55 C57BL/6 models, followed by a chronic phase in which persistent demyelination and axon degeneration drive ongoing neurological deterioration. In relapsing-remitting models (PLP-SJL), this is followed by further attack-remission cycles. Measuring visual function at a single end-point time point captures only a snapshot of this dynamic process, and – because visual recovery can occur between relapses – end-point measurements may miss the functional disability accumulated over the full disease course. Longitudinal optical acuity tracking in the same animals provides a continuous functional record that correlates with EAE severity scores, optic nerve histology, and molecular neuroinflammatory markers across the full disease trajectory.

Classical visual assessment methods – ERG and VEP – require anaesthesia and specialised electrophysiology equipment, and in the EAE context carry the additional confound that anaesthesia alters neuroinflammatory signalling, potentially blunting or exaggerating the measured response. The OptoDrum’s anaesthesia-free, automated paradigm eliminates both problems, delivering a functional visual acuity measurement that can be repeated daily during peak EAE without any additional procedural burden. Remlinger et al (2022) demonstrated that this approach is sensitive enough to detect the differential visual outcomes produced by FcRn blockade in an antibody-driven EAE/MOG model (Remlinger et al, 2022), and Morin et al (2021) used OptoDrum to confirm histaminergic modulation of EAE as a functional visual endpoint (Morin et al, 2021). Capper et al (2025) showed that OptoDrum detects diet-driven differences in EAE visual outcomes, confirming its sensitivity across a range of effect sizes and intervention types (Capper et al, 2025).

An important consideration for MS researchers is the distinction between subcortical and cortical visual pathway involvement. The OptoDrum measures the OMR, which is mediated by the subcortical accessory optic system and is therefore sensitive to retinal and optic nerve damage but not to selective cortical demyelination. In EAE models with significant cortical lesion burden, AcuiSee provides the complementary cortical endpoint: its operant forced-choice paradigm requires cortical visual processing and specifically detects deficits arising from demyelinating lesions in the optic radiation, lateral geniculate nucleus, or primary visual cortex. This distinction is particularly relevant for models of progressive MS in which cortical atrophy is a key pathological feature. For the full EAE/MS publication landscape, see also the Experimental Autoimmune Encephalomyelitis cluster page and the Multiple Sclerosis cluster page.

Mechanistic neuroinflammation research produces a rich catalogue of molecular findings – elevated cytokine levels, complement deposition, microglial transcriptomic signatures, axon degeneration markers – but connecting these molecular events to a functionally meaningful visual outcome requires a behavioural endpoint that integrates the combined effect of all these processes on the retina-to-brainstem pathway. This integration is precisely what the OptoDrum provides. A single OptoDrum measurement captures the cumulative functional effect of everything happening between the photoreceptor and the brainstem: if TNF-alpha is killing RGCs, if complement is disrupting synaptic function, if axon degeneration is reducing optic nerve conduction fidelity – all of these processes will reduce the optomotor acuity threshold in a graded, dose-sensitive way.

TNF-alpha is the most therapeutically targeted neuroinflammatory cytokine in both experimental and clinical autoimmune CNS disease. Its role in RGC death is well established: TNF receptor 1 (TNFR1) activation triggers both apoptotic and necrotic RGC death cascades, while TNF receptor 2 (TNFR2) may have neuroprotective functions in some contexts. Li et al (2025) used OptoDrum to demonstrate the functional magnitude of TNF-alpha-driven RGC degeneration, establishing the OMR as a sensitive endpoint for testing TNFR-selective therapeutic strategies (Li et al, 2025). Complement activation – a parallel amplification system engaged downstream of both antibody- mediated and innate immune triggers – was validated as a visual dysfunction driver by Zhao et al (2025), who demonstrated that C3/C3aR inhibition preserves OMR-measured visual acuity (Zhao et al, 2025). For the optic nerve damage and axon degeneration cluster pages, see Optic Nerve Damage, Retinal Ganglion Cell Death, and Retinal Ganglion Cell Dysfunction. For the broader retinal degeneration context, see the Retinal Degeneration and Inherited Retinal Disease application page and the Retinal Degeneration cluster page. The glaucoma connection is relevant here too – elevated IOP, neuroinflammation, and RGC loss share mechanisms – see the Glaucoma and Optic Nerve Neurodegeneration application page and the Glaucoma cluster page.

Optic neuritis in rodent EAE and related models follows a reproducible time course that mirrors the human clinical course in its broad features but compresses the time frame: acute demyelination and optic nerve inflammation typically peak between days 12 and 20 post- immunisation in MOG-EAE, producing rapid RGC loss and visual acuity decline; partial remyelination and some functional recovery may follow, but a proportion of RGCs are permanently lost due to secondary axon degeneration. Identifying the therapeutic window within which an intervention must be applied to prevent this secondary irreversible loss is one of the most clinically consequential questions in optic neuritis research.

The mechanistic complexity of optic neuritis – involving T cell and B cell infiltration of the optic nerve, microglial activation, oligodendrocyte and myelin loss, axon degeneration driven by energy failure and calcium overload, and secondary RGC apoptosis via deprivation of retro-axonal trophic support – means that individual histological and molecular endpoints each capture only one component of the overall pathological process. OptoDrum provides the integrative functional endpoint that reflects the combined output of all these processes: the optomotor acuity threshold declines when enough optic nerve conduction fidelity has been lost to impair the visual signal reaching brainstem targets, regardless of which specific pathological mechanism drove that loss.

The key insight from Groh et al (2025) is that microglial CX3CR1 signalling is a central orchestrator of optic nerve demyelination, providing a specific molecular target whose inhibition alters the functional visual trajectory in a way OptoDrum can detect longitudinally (Groh et al, 2025, Nat Neurosci). This type of longitudinal OptoDrum monitoring – with pre-immunisation baseline, repeated measurements through the acute phase, and tracking into the chronic or remission phase – is the design recommended for any study aiming to characterise the timing and kinetics of optic neuritis onset and recovery. For the dedicated cluster pages, see Optic Neuritis, Autoimmune Demyelinating Diseases, Axon Degeneration, and Glial Suppression. For the ocular inflammation context, see the Ocular Inflammation and Immune-Mediated Eye Disease application page.

MOGAD and NMOSD have been recognised as entities distinct from MS only in the last decade, and their preclinical modelling remains less standardised than EAE. The key pathological distinction is the effector mechanism: NMOSD is driven primarily by aquaporin-4 antibody (AQP4-IgG) attack on astrocytic endfeet, producing tissue-destructive lesions at the blood-CNS barrier; MOGAD is driven by MOG-IgG attack on oligodendrocyte cell surfaces and myelin. Both produce more severe optic neuritis than classical T cell-driven EAE, with less tendency for spontaneous remission, more extensive RGC loss, and greater functional visual deficits at equivalent disease duration. These clinical and pathological differences must be captured by the functional endpoint used in preclinical model development: an endpoint insensitive to the difference between EAE and MOGAD visual profiles cannot serve as a valid translational model characterisation tool.

OptoDrum provides the necessary discriminating sensitivity. Its graded threshold-seeking algorithm detects visual acuity across the full range from near-normal to near-abolished, making it capable of documenting the more severe and sustained deficits characteristic of MOGAD/NMOSD models as well as the partial, fluctuating deficits of classical relapsing- remitting EAE. Remlinger et al (2023) exploited this range to characterise the distinct visual deficit profile of NMOSD/MOGAD in rodents, providing a functional benchmark against which therapeutic interventions in these models can be evaluated (Remlinger et al, 2023). For the dedicated MOG and autoimmune demyelinating disease cluster pages, see MOG Antibody-Associated Disorder, Autoimmune Demyelinating Diseases, Experimental Autoimmune Encephalomyelitis, and Multiple Sclerosis. For the ocular inflammation context of antibody-mediated optic nerve disease, see the Ocular Inflammation and Immune-Mediated Eye Disease application page.

The preclinical MS and optic neuritis field has a well-documented translational gap: many interventions that reduce clinical EAE scores, decrease spinal cord lesion burden, or improve histological RGC counts fail to produce robust functional visual recovery as measured by behavioural endpoints. This gap exists because EAE clinical scoring (predominantly measuring hindlimb paralysis) does not capture optic nerve functional integrity, and because histological RGC counts confirm cell survival but not whether surviving cells are functionally contributing to the visual circuit. OptoDrum bridges this gap by providing the behavioural functional endpoint that confirms whether a neuroprotective or immunomodulatory treatment has actually preserved the retina-to-brainstem visual pathway sufficiently to support a tracking response.

The EAE neuroprotection literature has moved beyond classical immunosuppression to target specific molecular pathways: HIF-1-driven hypoxia in demyelinating lesions (Anders et al, 2023), BET protein-dependent inflammatory transcription (Zhu et al, 2023), cholesterol metabolism (Godwin et al, 2022, covered in FAQ 3), and optic nerve regeneration through Nogo-A pathway inhibition (Baya Mdzomba et al, 2020). Each of these intervention strategies has been validated with OptoDrum as the functional visual endpoint, providing a set of published precedents for researchers designing new neuroprotection studies in this application area. For the optic nerve regeneration angle, see the Optic Nerve Regeneration cluster page. For the therapeutic vision restoration context, see the Gene Therapy, Optogenetics and Regeneration application page.

CNS neuroinflammation research in areas outside ophthalmology – brain inflammation, spinal cord disease, meningitis, encephalitis, systemic autoimmunity – faces the fundamental problem that CNS functional endpoints are difficult to measure non-invasively in rodents. Motor scoring (rotarod, beam walk, EAE clinical scale), cognitive tests (Morris water maze, novel object recognition), and biopsy or imaging-dependent measures each capture one aspect of CNS function but require significant procedural resources, suffer from high variability and floor/ceiling effects, or are terminal. Visual acuity measured by OptoDrum provides a non-invasive, rapidly repeatable, quantitative CNS functional endpoint that can be incorporated into any neuroinflammatory research protocol at minimal additional cost, simultaneously with other behavioural and imaging assessments.

The scientific basis for this biomarker argument is solid. Sheng et al (2026) demonstrated that neuroinflammatory amyloid accumulation in the retina – a hallmark of Alzheimer’s disease pathology – produces OptoDrum-measurable visual acuity deficits, validating visual function as a biomarker of neuroinflammatory burden in a non-demyelinating neurodegenerative context (Sheng et al, 2026). Kinuthia et al (2025) demonstrated that OptoDrum tracks the functional visual benefit of immunomodulation in inflammatory retinopathy with metabolic overlap (Kinuthia et al, 2025), and Xue et al (2023) showed that alleviating ischaemic demyelination preserves OptoDrum- measured visual function, bridging vascular and neuroinflammatory mechanisms (Xue et al, 2023). For the Alzheimer’s disease biomarker context, see the Alzheimer’s Disease cluster page. For the retinal degeneration cluster cross-reference, see Retinal Degeneration. For the ischaemia and vascular disease angle, see the Vascular and Metabolic Disease application page, the Retinal Ischaemia-Reperfusion Injury cluster page, and the Blindness cluster page.

Progressive CNS diseases – whether age-related, rare-inherited, or degenerative – typically evolve over months to years, demanding monitoring tools that are practical for long-duration studies in the same animals, non-invasive enough to avoid cumulative welfare burden, and sensitive enough to detect gradual functional changes that might be missed by infrequent end-point measurements. Rare inherited neuroinflammatory CNS diseases present the additional challenge that most are ultrarare, meaning that any given research laboratory works with a small number of animals and cannot afford to sacrifice animals at multiple time points for histological monitoring – each animal must provide repeated functional data points across the study.

OptoDrum is ideally designed for this role. Its four-minute, anaesthesia-free paradigm is low enough burden to be applied weekly or even more frequently in long-duration natural history or treatment studies, generating a rich longitudinal dataset of visual function trajectories in the same animals across the full study period. In aging studies, this longitudinal sensitivity was demonstrated by Groh et al (2021, Nat Aging), who tracked progressive visual acuity loss as a readout of immunosenescence-driven CNS axon degeneration across the mouse lifespan (Groh et al, 2021, Nat Aging). In rare disease models, the same approach was validated in CLN1 disease by Groh et al (2021, Brain Commun) (Groh et al, 2021) and in HSP by Horner et al (2024) (Horner et al, 2024). The sex-dimorphic microglial dynamics documented by Berve et al (2020) add an important experimental design consideration: researchers studying microglial neuroinflammation in rare or aging models should include sex as a biological variable and track visual function separately in male and female cohorts (Berve et al, 2020).

For the rare inherited disease context, see the Rare and Inherited CNS and Eye Disorders application page and the Rare Disease cluster page. For the aging and aging-neuroinflammation intersection, see the Systemic Aging and CNS Decline application page and the Aging cluster page. The axon degeneration cluster is directly relevant to all contexts in this FAQ: see the Axon Degeneration cluster page. For the Alzheimer’s disease and neurodegeneration overlap, see the Alzheimer’s Disease and Age-Related Macular Degeneration cluster pages.